Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OCX Stock Forecast 2026-2027
$4.71
Current Price
$82.20M
Market Cap
Buy 2
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to OCX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
OCX Price Momentum
-7.3%
1 Week Change
-13.4%
1 Month Change
+64.7%
1 Year Change
-37.2%
Year-to-Date Change
-44.7%
From 52W High of $8.51
+102.1%
From 52W Low of $2.33
📊 TOP ANALYST CALLS
Did OCX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Oncocyte is one of their latest high-conviction picks.
Latest OCX Stock Price Targets & Analyst Predictions
OCX has shown a year-to-date change of -37.2% and a 1-year change of 64.7%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for OCX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OCX Analyst Ratings
2
Buy
2
Hold
0
Sell
OCX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $4.71
Latest OCX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OCX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 21, 2025 | Lake Street | Thomas Flaten | Buy | Maintains | $8.00 |
| May 13, 2025 | Needham | Mike Matson | Buy | Reiterates | $4.25 |
| Apr 8, 2025 | Needham | Mike Matson | Buy | Reiterates | $4.25 |
| Mar 28, 2025 | Lake Street | Thomas Flaten | Buy | Initiates | $5.00 |
| Mar 26, 2025 | Stephens & Co. | Mason Carrico | Equal-Weight | Reiterates | $4.00 |
| Mar 25, 2025 | Stephens & Co. | Mason Carrico | Equal-Weight | Reiterates | $4.00 |
| Mar 25, 2025 | Needham | Mike Matson | Buy | Reiterates | $4.25 |
| Nov 13, 2024 | Needham | Mike Matson | Buy | Reiterates | $4.25 |
| Oct 15, 2024 | Needham | Mike Matson | Buy | Reiterates | $4.25 |
| Aug 9, 2024 | Needham | Mike Matson | Buy | Reiterates | $4.25 |
| May 16, 2024 | Needham | Mike Matson | Buy | Reiterates | $4.25 |
| Apr 24, 2024 | Needham | Mike Matson | Buy | Maintains | $4.25 |
| Apr 17, 2024 | Stephens & Co. | Mason Carrico | Equal-Weight | Reiterates | $4.00 |
| Apr 15, 2024 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $5.00 |
| Nov 13, 2023 | Piper Sandler | David Westenberg | Neutral | Maintains | $3.00 |
| Nov 9, 2023 | Needham | Mike Matson | Buy | Maintains | $3.60 |
| Aug 24, 2023 | Benchmark | Bruce Jackson | Speculative Buy | Maintains | $5.00 |
| Aug 15, 2023 | Piper Sandler | David Westenberg | Neutral | Maintains | $3.50 |
| Aug 10, 2023 | Needham | Mike Matson | Buy | Maintains | $4.25 |
| Apr 4, 2023 | Needham | Mike Matson | Buy | Maintains | $0.45 |
Insight Molecular Diagnostics Inc. (OCX) Competitors
The following stocks are similar to Oncocyte based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Insight Molecular Diagnostics Inc. (OCX) Financial Data
Insight Molecular Diagnostics Inc. has a market capitalization of $82.20M with a P/E ratio of -1.0x. The company generates $1.88M in trailing twelve-month revenue with a 39.3% profit margin.
Revenue growth is -75.8% quarter-over-quarter, while maintaining an operating margin of -3,220.6% and return on equity of +496.4%.
Valuation Metrics
Market Cap
$82.20M
Enterprise Value
$77.23M
P/E Ratio
-1.0x
PEG Ratio
0.1x
Price/Sales
43.7x
Growth & Margins
Revenue Growth (YoY)
-75.8%
Gross Margin
+67.6%
Operating Margin
-3,220.6%
Net Margin
+39.3%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
N/A
Current Ratio
4.0x
Debt/Equity
3.1x
ROE
+496.4%
ROA
-173.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Insight Molecular Diagnostics Inc. (OCX) Business Model
About Insight Molecular Diagnostics Inc.
What They Do
Develops advanced molecular diagnostic tests.
Business Model
The company generates revenue by developing and commercializing precision diagnostic tests for clinical and research applications, particularly in transplant medicine and oncology. Its offerings include laboratory-developed tests and kitted assays, which address key unmet needs in patient care and are sold to healthcare providers and pharmaceutical partners.
Additional Information
Founded in 2009 and headquartered in Nashville, Insight Molecular Diagnostics is known for its innovative products like the VitaGraft tests for organ transplant monitoring and Determa assays for cancer treatment. The company collaborates with industry leaders such as Bio-Rad Laboratories to advance research and in-vitro diagnostics, aiming to improve patient outcomes through personalized healthcare solutions.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
55
CEO
Mr. Joshua Riggs
Country
United States
IPO Year
2016
Website
www.imdxinc.comInsight Molecular Diagnostics Inc. (OCX) Latest News & Analysis
Latest News
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
1 year ago
Quick Summary
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX), previously Oncocyte Corporation, has rebranded and relocated its headquarters to Nashville, focusing on precision biomarker testing and sponsoring research kits.
Why It Matters
The rebranding and focus on precision biomarker testing may enhance iMDx's market position and growth prospects, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oncocyte Corp. (Nasdaq: OCX) announced a favorable reimbursement rate for its GraftAssureCore test, enhancing its position in the transplant rejection testing market with a potential $1 billion market opportunity.
Why It Matters
Oncocyte Corp.'s positive reimbursement update for GraftAssureCore enhances its market position and growth potential in the $1 billion transplant rejection testing sector, signaling potential revenue increases.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
OncoCyte Corporation (NASDAQ: OCX) will hold its Q1 2025 earnings conference call on May 12, 2025, at 5:00 PM ET with key executives participating.
Why It Matters
OncoCyte's Q1 earnings call could reveal performance metrics and strategic insights that impact stock valuation and investor sentiment regarding the company's growth potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Oncocyte Corp. (Nasdaq: OCX) released a letter to shareholders alongside its first-quarter results on May 12, 2025.
Why It Matters
Oncocyte's shareholder letter and Q1 results can indicate financial health and strategic direction, influencing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oncocyte Corp. (Nasdaq: OCX) will report its Q1 2025 financial results after market close on May 12, 2025.
Why It Matters
Oncocyte Corp.'s upcoming financial results could impact stock performance, investor sentiment, and market valuation based on growth or challenges reflected in the report.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Best Momentum Stocks to Buy for May 6th
1 year ago
Quick Summary
MAIA, BYRN, and OCX are ranked #1 (Strong Buy) by Zacks as of May 6, 2025, indicating strong momentum for these stocks.
Why It Matters
MAIA, BYRN, and OCX being ranked as Strong Buy indicates strong potential for price appreciation, attracting investors seeking growth opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About OCX Stock
What is Insight Molecular Diagnostics Inc.'s (OCX) stock forecast for 2027?
Analyst forecasts for Insight Molecular Diagnostics Inc. (OCX) are not currently available. The stock is trading at $4.71.
Is OCX stock a good investment in 2027?
According to current analyst ratings, OCX has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.71. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OCX stock?
Price predictions from Wall Street analysts for OCX are not currently available. The stock is trading at $4.71.
What is Insight Molecular Diagnostics Inc.'s business model?
The company generates revenue by developing and commercializing precision diagnostic tests for clinical and research applications, particularly in transplant medicine and oncology. Its offerings include laboratory-developed tests and kitted assays, which address key unmet needs in patient care and are sold to healthcare providers and pharmaceutical partners.
What is the highest forecasted price for OCX Insight Molecular Diagnostics Inc.?
Price targets from Wall Street analysts for OCX are not currently available. The stock is trading at $4.71.
What is the lowest forecasted price for OCX Insight Molecular Diagnostics Inc.?
Price targets from Wall Street analysts for OCX are not currently available. The stock is trading at $4.71.
What is the overall OCX consensus from analysts for Insight Molecular Diagnostics Inc.?
The overall analyst consensus for OCX is neutral. Out of 9 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell.
How accurate are OCX stock price projections?
Stock price projections, including those for Insight Molecular Diagnostics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:30 PM UTC